Christopher Recknor

2.2k citations

27 papers · 1.6k indexed · h-index 17

Impact in

Orthopedics and Sports Medicine top 0.5%
- Bone health and osteoporosis research
- Bone and Joint Diseases
Oncology top 5%
- Bone health and treatments

Papers in ⓘ

Orthopedics and Sports Medicine 19
- Bone health and osteoporosis research 18
Oncology 18
- Bone health and treatments 16
- Cytokine Signaling Pathways and Interactions 1

Co-authors: Bruce Mitlak (3 shared papers)Mark Lakshmanan (2 shared papers)Harry K. Genant (2 shared papers)John H. Krege (5 shared papers)Pedro Alberto García-Hernández (1 shared paper)Kelly Krohn (1 shared paper)Kyoungah See (1 shared paper)Thomas A. Einhorn (1 shared paper)
Journals: Journal of Bone and Mineral Research (6 papers)Bone (4 papers)The Journal of Clinical Endocrinology & Metabolism (3 papers)Osteoporosis International (2 papers)Therapeutic Advances in Musculoskeletal Disease (1 paper)
Partner nations: United States Canada France

In The Last Decade

Christopher Recknor

26 papers receiving 1.6k citations

Peers

Countries citing papers authored by Christopher Recknor

Since Specialization

Citations

This map shows the geographic impact of Christopher Recknor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Recknor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Recknor more than expected).

Fields of papers citing papers by Christopher Recknor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Recknor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Recknor. The network helps show where Christopher Recknor may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher Recknor, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Recknor Line = papers co-authored together Christopher Recknor links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures Journal of Bone and Mineral Research ·Per Aspenberg, Harry K. Genant, Torsten Johansson, Antonio Nino, Kyoungah See, Kelly Krohn, Pedro Alberto García-Hernández, Christopher Recknor, Thomas A. Einhorn, G. P. Dalsky, Bruce Mitlak, Anke Fierlinger, Mark Lakshmanan	2009	402
2	Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial The Lancet Diabetes & Endocrinology ·Clemens Becker, Stephen R. Lord, Stephanie A. Studenski, Stuart J. Warden, Roger A. Fielding, Christopher Recknor, Marc C. Hochberg, Serge Ferrari, Hubert Blain, Ellen F. Binder, Yves Rolland, Serge Poiraudeau, Charles Benson, Stephen L. Myers, Leijun Hu, Qasim Ahmad, Kelli R Pacuch, Elisa V Gomez, Olivier Bénichou	2015	279
3	Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent The Journal of Clinical Endocrinology & Metabolism ·Felicia Cosman, Robert A. Wermers, Christopher Recknor, Karen F. Mauck, Li Xie, Emmett V. Glass, John H. Krege	2009	125
4	Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial Journal of Bone and Mineral Research ·Jacques P. Brown, Christian Roux, Ove Törring, Pei‐Ran Ho, Jens‐Erik Beck Jensen, Nigel Gilchrist, Christopher Recknor, Matt Austin, Andrea Wang, Andreas Grauer, Rachel B. Wagman	2012	108
5	Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial The Journal of the American Dental Association ·John T. Grbic, Regina Landesberg, Shouqing Lin, Peter Mesenbrink, Ian R. Reid, Ping‐Chung Leung, Noemí Casas, Christopher Recknor, Hua Ye, Pierre D. Delmas, Erik Fink Eriksen	2008	104
6	The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures Osteoporosis International ·Peyman Hadji, José Zanchetta, Luis Augusto Tavares Russo, Christopher Recknor, Kenneth G. Saag, Fergus E. McKiernan, Stuart L. Silverman, Jahangir Alam, Russel Burge, John H. Krege, Mark Lakshmanan, Daniel N. Masica, Bruce Mitlak, John L. Stock	2011	98
7	Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial The Journal of Clinical Endocrinology & Metabolism ·David W. Dempster, Hua Zhou, Robert R. Recker, Jacques P. Brown, Michael A. Bolognese, Christopher Recknor, David L. Kendler, E. Michael Lewiecki, David A. Hanley, D. Sudhaker Rao, Paul D. Miller, Grattan C. Woodson, Robert Lindsay, Neil Binkley, Xiaohai Wan, Valerie A. Ruff, Boris Janos, Kathleen A. Taylor	2012	63
8	The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density Journal of Bone and Mineral Research ·Christopher Recknor, Robert R. Recker, Charles Benson, Deborah A. Robins, Alan Y. Chiang, Jahangir Alam, Leijun Hu, Toshio Matsumoto, Hideaki Sowa, John H. Sloan, Robert J. Konrad, Bruce Mitlak, Adrien Sipos	2015	60
9	Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study Journal of Bone and Mineral Research ·David W. Dempster, Hua Zhou, Robert R. Recker, Jacques P. Brown, Christopher Recknor, E. Michael Lewiecki, Paul D. Miller, Sudhaker D. Rao, David L. Kendler, Robert S. Lindsay, John H. Krege, Jahangir Alam, Kathleen A. Taylor, Thomas Melby, Valerie A. Ruff	2017	53
10	Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass Bone ·Robert R. Recker, David L. Kendler, Christopher Recknor, Theodore W. Rooney, E. Michael Lewiecki, Wulf H. Utian, Jane A. Cauley, Joanne Lorraine, Yongming Qu, Pandurang M. Kulkarni, C. Gaich, Mayme Wong, Leo Plouffe, John L. Stock	2006	51
11	Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study The Journal of Clinical Endocrinology & Metabolism ·David W. Dempster, Hua Zhou, Robert R. Recker, Jacques P. Brown, Christopher Recknor, E. Michael Lewiecki, Paul D. Miller, Sudhaker D. Rao, David L. Kendler, R. Lindsay, John H. Krege, Jahangir Alam, Kathleen A. Taylor, Boris Janos, Valerie A. Ruff	2016	48
12	Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial Journal of Bone and Mineral Research ·Jacques P. Brown, Klaus Engelke, Tony M. Keaveny, Arkadi Chines, Roland Chapurlat, A. Joseph Foldes, Xavier Nogués, Roberto Civitelli, Tobias De Villiers, Fabio Massari, Cristiano A. F. Zerbini, Zhenxun Wang, Mary Oates, Christopher Recknor, Cesar Libanati	2021	44
13	Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate Osteoporosis International ·Jacques P. Brown, Christian Roux, Pei‐Ran Ho, Michael A. Bolognese, Jesse Hall, Henry G. Bone, Sydney Lou Bonnick, Joop P. van den Bergh, I. Ferreira, Paula Dakin, Rachel B. Wagman, Christopher Recknor	2014	44
14	Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology Bone ·Philippe K. Zysset, Dieter H. Pahr, Klaus Engelke, Harry K. Genant, Michael R. McClung, David L. Kendler, Christopher Recknor, Michael Kinzl, Jakob Schwiedrzik, Oleg Museyko, Andrea Wang, Cesar Libanati	2015	42
15	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis Menopause The Journal of The North American Menopause Society ·James A. Simon, Christopher Recknor, Alfred H. Moffett, Jonathan D. Adachi, Edward Franek, E. Michael Lewiecki, Michael R. McClung, C. Mautalén, Sergio Ragi-Eis, Geoffrey C. Nicholson, Christian Muschitz, Ranuccio Nuti, Ove Törring, Andrea Wang, Cesar Libanati	2012	32
16	A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial Journal of Bone and Mineral Research ·David W. Dempster, Hua Zhou, Robert R. Recker, Jacques P. Brown, Michael A. Bolognese, Christopher Recknor, David L. Kendler, E. Michael Lewiecki, David A. Hanley, Sudhaker D. Rao, Paul D. Miller, Grattan C. Woodson, R. Lindsay, Neil Binkley, Jahangir Alam, Valerie A. Ruff, Eileen R. Gallagher, Kathleen A. Taylor	2016	32
17	Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study Clinical Therapeutics ·Ronald Emkey, Pierre D. Delmas, Michael A. Bolognese, João Lindolfo Cunha Borges, Felicia Cosman, Sergio Ragi-Eis, Christopher Recknor, Cristiano A. F. Zerbini, Colin Neate, Farhad Sedarati, Solomon Epstein	2009	26
18	Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome Clinical Infectious Diseases ·Norman Gaylis, Angela Ritter, Scott A. Kelly, Nader Pourhassan, Meenakshi Tiwary, Jonah B. Sacha, Scott G. Hansen, Christopher Recknor, Otto O. Yang	2022	16
19	Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC) Cancer Research ·Massimo Cristofanilli, Namita Chittoria, Sima Ehsani, Hallgeir Rui, Marek Doležal, Lisette Stork‐Sloots, Femke De Snoo, Christopher Recknor, Vandana G. Abramson	2022	6
20	Effects of Teriparatide in Postmenopausal Women With Osteoporosis on Prior Alendronate or Raloxifene: Differences Between Stopping and Continuing the Antiresorptive Agent Obstetrical & Gynecological Survey ·Felicia Cosman, Robert A. Wermers, Christopher Recknor, Karen F. Mauck, Li Xie, Emmett V. Glass, John H. Krege	2010	3

About Christopher Recknor

Christopher Recknor is a scholar working on Orthopedics and Sports Medicine, Oncology, Toxicology, Molecular Biology and Nephrology, having authored 27 papers that have together received 1.6k indexed citations. Recurring topics across this work include Bone health and osteoporosis research (18 papers), Bone health and treatments (16 papers), Bone Metabolism and Diseases (12 papers), Hip and Femur Fractures (2 papers), Nutrition and Health in Aging (2 papers), Pharmacovigilance and Adverse Drug Reactions (1 paper), Spine and Intervertebral Disc Pathology (1 paper) and Cytokine Signaling Pathways and Interactions (1 paper). The work is most often cited by research in Orthopedics and Sports Medicine (1.1k citations), Oncology (890 citations), Nephrology (68 citations), Molecular Biology (657 citations) and Physiology (227 citations). Christopher Recknor has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Bruce Mitlak, Mark Lakshmanan, Harry K. Genant, John H. Krege, Pedro Alberto García-Hernández, Kelly Krohn, Kyoungah See, Thomas A. Einhorn, G. P. Dalsky and Antonio Nino. Their work appears in journals such as Journal of Bone and Mineral Research, Bone, The Journal of Clinical Endocrinology & Metabolism, Osteoporosis International and Therapeutic Advances in Musculoskeletal Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact